Skip to content

Non-inferiority trial for treatment of mild to moderate gingivitis.

Non-inferiority efficacy study of 2 different formulations of 0.12% Chlorhexidine gluconate oral rinse with (Oroclense) and without alcohol (Oroclear) for treatment of gingivitis.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/05/001774
Enrollment
120
Registered
2011-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- mild to moderate gingivitis

Interventions

Intervention1: oroclear -oral rinse solution: 15 ml twice daily Chlorhexidine Gluconate is available as Chlorhexidine Gluconate Solution, USP. It is an almost colorless to pale straw-colored, clear o

Sponsors

Germiphene Corporation
Lead Sponsor
Semler Research Center Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects should have reasonable standard of oral hygiene with no severe gingivitis (score of not 2 on the Gingival Index). Basically subjects with mild to moderate gingivitis are considered. 2. Subjects should have probing depths of not more than 3mm. 3. Subjects should have a minimum of 20 natural teeth. 4. Subjects should have no physical limitations or restrictions that might preclude normal oral hygiene procedures such as toothbrushing. 5. Subjects should have no history of adverse reactions to mouthrinses or any of the ingredients in the said formulations. 6. Subjects should not have been using another prophylaxis rinse. If so then a 14 day washout period is required before induction into the clinical trial. 7. Subjects should be capable of providing their consent or if appropriate, have an acceptable surrogate capable of giving consent on the subject?s behalf to participate in the clinical trial after being given adequate information pertaining to the study. 8. Note: subjects that smoke or have diabetes should be considered within the study and effort should be made to obtain statistical significance. This is inclusive for pediatric (greater than 12 years old ? refer to point 9) and geriatric patients. 9. Pediatric patients should have good general health, a minimum of 12 gradable teeth, agreement to delay any elective dental treatment, including oral prophylaxis during the course of the study. Age minimum of 12 years old.

Exclusion criteria

Exclusion criteria: 1. Subjects with severe gingivitis or who have probing depths exceeding 3mm and alveolar bone loss. 2. Periodontitis as indicated by clinical attachment loss, radiographic alveolar bone loss, or periodontal pockets greater than 5 millimeters. Or history of early-onset periodontitis or acute necrotizing ulcerative gingivitis. 3. Concomitant endodontic or periodontal therapy other than prophylaxis in the last 6 months. 4. Gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaques or calculus, or soft or hard tissue tumor of the oral cavity. 5. Subjects who have consumed antibiotics in the past 6 months or having a conditions requiring antibiotic prophylaxis such as heart murmurs, pacemakers, prosthetic heart valves, as well as non-oral prosthetic implants. 6. History of rheumatic fever, congenital heart disorders, prosthetic heart valves or any other conditions requiring antibiotics prior to dental treatment. 7. Chronic disease with concomitant oral manifestations. 8. Orthodontic appliances or removable partial dentures. 9. Chronic treatment (2 weeks or more) with any medication known to affect periodontal status (including phenytoin, calcium antagonists, cyclosporine, coumarin, nonsterioidal anti-inflammatory drugs, and aspiring) within 1 month of the screening examination. All other medications for chronic medical conditions have been initiated at least 3 months before enrollment. 10. Homeless persons or those with active drug/alcohol dependence or abuse history. 11. Medical conditions or significant laboratory abnormalities that the investigator considers significant and that may compromise the subjects safety. 12. Subjects whose manual dexterity is compromises e.g. handicapped or post-stroke patients. 13. Subjects with known sensitivities to any of the formulation ingredients and to CHG.

Design outcomes

Primary

MeasureTime frame
The proportionate reduction for GI measurements is the comparison of the active Test therapy to the Reference therapy at the end of the studyTimepoint: periodic over a span of 7 months

Secondary

MeasureTime frame
Stain indicesTimepoint: Periodic

Countries

India

Contacts

Public ContactParijat Nandy
dranirbanchatterjee@yahoo.com080-41206229

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026